Marshall Wace LLP Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Marshall Wace LLP purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 24,501 shares of the company's stock, valued at approximately $577,000.

A number of other hedge funds have also recently made changes to their positions in the stock. KBC Group NV lifted its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $257,000. Magnetar Financial LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $263,000. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after buying an additional 1,249 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded up $1.12 during trading on Thursday, reaching $10.52. The company had a trading volume of 840,232 shares, compared to its average volume of 1,601,860. The firm's 50-day simple moving average is $10.40 and its 200 day simple moving average is $18.47. The firm has a market capitalization of $1.20 billion, a PE ratio of -2.96 and a beta of 1.19. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 6,237 shares of company stock valued at $77,760 over the last quarter. 20.77% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

DYN has been the subject of a number of research analyst reports. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price for the company. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Piper Sandler dropped their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.